EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetic Study and Bioequivalence Evaluation of Two Sustained‐Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions

Jie Wang, Fang Yao, Pan Lu, Yafang Xie, Xiuwen Li, Qiangwei Liu, Yang Liu, Dan Cao, Jun Liang, Ming Zhou

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1589 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Jie Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China. Hauptthemen laut MEDLINE: Adrenergic alpha-1 Receptor Antagonists, Tamsulosin. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tamsulosin is a highly selective α1A adrenergic receptor antagonist that can relax smooth muscles in the urethra, bladder neck, and prostate and improve urinary disorders. It is therefore widely used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. The aim of this study is to evaluate the pharmacokinetic (PK) characteristics and bioequivalence of 2 different formulations (tamsulosin sustained‐release tablets and tamsulosin sustained‐release capsules) in healthy Chinese subjects. This study was a single‐center, randomized, open label, 2‐formulation, single‐administration, 2‐cycle, double‐crossover fasting/postprandial bioequivalence trial that included 56 healthy volunteers (28 fasting and 28 postprandial). Blood samples were collected from volunteers after oral administration, plasma concentrations of tamsulosin were determined by liquid chromatography‐tandem mass spectrometry for PK analysis, and the safety and tolerability of the drug were monitored. Under fasting and postprandial conditions, the 90% confidence intervals for maximum observed concentration (C max ) and area under the plasma concentration‐time curve from time 0 to the last sampling time (AUC 0‐t ) of the test and reference formulations were within an acceptable range (80%‐125%). All adverse events (AEs) were mild and no serious AEs were observed in the study. The subject formulation of tamsulosin extended‐release tablets was safe and well tolerated in healthy Chinese Volunteers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic alpha-1 Receptor AntagonistsTamsulosinAdultHumansMaleYoung AdultAdministration, OralArea Under CurveCross-Over StudiesDelayed-Action PreparationsFastingHealthy VolunteersPostprandial PeriodTabletsTherapeutic EquivalencyEast Asian People

Stichwörter der Autor:innen

bioequivalencehealthy subjectspharmacokineticssafetytamsulosin extended‐release tablets

Substanzen

Adrenergic alpha-1 Receptor AntagonistsDelayed-Action PreparationsTabletsTamsulosin

Autor:innen und Institutionen

  • Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China.

Zitieren

APA

Wang, J., Yao, F., Lu, P., Xie, Y., Li, X., Liu, Q., Liu, Y., Cao, D., Liang, J., & Zhou, M. (2025). Pharmacokinetic Study and Bioequivalence Evaluation of Two Sustained‐Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1589

Vancouver

Wang J, Yao F, Lu P, Xie Y, Li X, Liu Q, et al. Pharmacokinetic Study and Bioequivalence Evaluation of Two Sustained‐Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1589

BibTeX
@article{Wang2025,
  author = {Wang, Jie and Yao, Fang and Lu, Pan and Xie, Yafang and Li, Xiuwen and Liu, Qiangwei and Liu, Yang and Cao, Dan and Liang, Jun and Zhou, Ming},
  title = {Pharmacokinetic Study and Bioequivalence Evaluation of Two Sustained‐Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1589}
}
Kostenlos starten →